Company ProfilePremium

Max Sight Group Holdings Limited

Company Profile Analysis

Ticker: 8483.HK名仕快相集團控股有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Max Sight Group Holdings Limited - Company showcase

Year Founded & Workforce

1989

45 Employees

Max Sight Group Holdings Limited logo

Max Sight Group Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Max Sight Group Holdings Limited Overview

MetricFY2021FY2022FY2023FY2024FY2025
Employees at year end (headcount)—64786447

Max Sight Group is a micro-cap Hong Kong consumer-services company that for more than three decades has operated a network of automatic identity-document (ID) photo booths under the "Max Sight Photo" brand, positioned in metro stations, ID and visa application centres, universities, hospitals and shopping malls. Since October 2021 it has diversified into primary-care medical services through a small network of general-practice clinics branded "Max Medical", which in FY2025 overtook photography as the larger revenue line. The photo-booth franchise — historically high-margin and supplied by ME Group (Photo-Me) — is in structural decline as Hong Kong's Immigration Department digitises ID-photo capture through Personal Document Submission Kiosks and visa processes move online, and following the April 2025 expiry of a major government-site service contract. With revenue down 45% from its FY2023 post-COVID peak, rising losses and thin equity, the company was acquired in July 2026 by entrepreneur Li Xiangpu, whose plans beyond maintaining the existing businesses and listing remain undisclosed.


Company's own description

In its FY2025 Annual Report and FY2026 interim filings, the company describes itself as principally engaged in (i) providing photography services through automatic ID photo booths in Hong Kong (and, until 2025, Guangdong Province), and (ii) providing medical services by operating medical centres in Hong Kong, with a focus on general practice — primary care for acute illness and chronic disease management, routine health screenings, vaccinations and specialist referrals (IRA H1 2026). The company's website characterises it as a leading automatic ID photo-booth operator in Hong Kong and Guangdong, with a service promise summarised as precise validation and simple photography, backed by an "unconditional guarantee" of a free retake or full refund if a customer is dissatisfied with a photo (company website, accessed October 2026).

The medical business is described as offering physical-examination plans, vaccination services, outreach doctor services, and sales of therapeutic services and wellness merchandise, alongside community medical benefit programmes (company website).

Business model and revenue model

Revenue streamModelRecognitionFY2025 revenue (HKD Mn)Share of total
ID photo booth services (retail)Pay-per-use self-service kiosks; cash and smart-card (Octopus-type) payment; site licences paid to landlords on fixed, revenue-share or higher-of basisPoint in timePart of 21.19047.6% (photography total)
Sale of photo strips / consumables to an institutional customerProduct sale — replaced a service contract at government ID/visa sites after it matured in April 2025Point in timePart of 21.190(included above)
Medical consultation and related servicesFee-for-service GP consultations; vaccinations; health screening; medical cards via network agents; HK Government Elderly Health Care VouchersPoint in time23.30552.4%

Source: ARA FY2025 note 2; IRA H1 2026 notes 4 and 12.

The revenue model is 100% transactional — no subscription or licensing revenue is disclosed. All revenue is recognised at a point in time (ARA FY2025). No single customer exceeded 10% of revenue in FY2024, FY2025 or H1 2026 (ARA FY2025; IRA H1 2026).

Value-chain position

Photography: Max Sight sits at the operator/retail end of the value chain. It does not manufacture booths; booths and consumables have historically been sourced from ME Group International plc (formerly Photo-Me International plc), a relationship dating from 1993 and formalised in a Master Supply Agreement dated 4 August 2023 covering FY2023–FY2025 with annual caps of HK$1 M for booths and HK$3 M for consumables (AR 2023, AR 2025). Its key upstream dependency is landlords/licensors (MTR stations, government buildings, malls, universities) that grant booth sites.

Medical: The Group owns and operates clinic premises and engages doctors partly through consultancy companies that are also minority shareholders in clinic-holding subsidiaries (Echo Bay Consultant Company Limited holds 19% of Speed Dragon Development Limited; Mingway Health Limited holds 20% of Wealthy Dragon Development Limited) and are paid a fixed monthly fee plus profit share (Company announcement, 25 Sep 2026).

Customer types and end-markets

End-marketCustomer typeKey demand drivers
ID photography (Hong Kong)General public needing passport, HKID, visa, travel permit, student and licence photosDocument renewal cycles; travel demand; immigration schemes (e.g., Top Talent Pass Scheme from 2022–23); government document digitisation (negative)
ID photography (Guangdong)General publicLargely displaced by PRC online applications with digital photos and face recognition (ARA FY2025) — operations wound down by end-2025
Primary care (Hong Kong)Walk-in patients, medical-card holders via network agents, elderly using healthcare vouchersSeasonal influenza; HK Primary Healthcare Blueprint; Hospital Authority fee reform effective 1 Jan 2026

Independent characterisation

Max Sight is best understood as a sub-scale, family-built, cash-generative-at-peak niche operator that has been caught between two structural shifts: (1) the digital substitution of physical ID photos, which is eroding a historically high-margin core; and (2) an unsuccessful attempt to scale a diversification into primary care, which, while stable at roughly HK$22–23 M of revenue, generates segment margins in the mid-single digits and has not expanded beyond its existing clinics since 2023 because "no suitable project was identified" (ARA FY2025). The July 2026 sale of 75% of the company at HK$0.0875 per share — a 22% discount to the prior closing price but a 376% premium to book value — is consistent with a transaction priced substantially on the value of the GEM listing platform itself (JA 27 Jul 2026). Post-transaction, the strategic direction is effectively a blank page pending the new controller's review.

Strategy

Stated strategy (legacy management, AR 2025 and IRA H1 2026)

The pre-transaction strategy, paraphrased from the FY2025 Chairman's Statement and MD&A, rested on four themes:

  1. Defend photography share through quality and coverage — management repeatedly asserted that substantial ID-photo demand will persist in Hong Kong and that service quality and site coverage drive share; resources were reallocated to booth hardware/software upgrades, booth decoration, staff training, advertising, and site-by-site profitability reviews with relocations (ARA FY2025).

  2. Explore digital adaptation — meetings with partners and vendors to upgrade IT infrastructure and assess delivering digital ID photos through existing booths (ARA FY2025).

  3. Build medical into a recurring-income pillar — expand the medical team, scope of services and clinic network; obtain clinic licences under the Private Healthcare Facilities Ordinance (Cap. 633); position for the Primary Healthcare Blueprint and the Hospital Authority fee reform effective 1 Jan 2026 (ARA FY2025).

  4. Diversify and broaden revenue base — continued research into new business opportunities (generic, no specifics).

Initiatives register (last 24 months)

DateInitiativeStatus / outcomeSource
Ongoing 2024–2026Booth upgrade and marketing programme (IPO proceeds: HK$4.24 M allocated; HK$2.44 M used by 30 Jun 2026)In progress; unutilised HK$1.80 M to be used by 31 Dec 2026IRA H1 2026
Ongoing 2024–2026Medical business development (HK$5.65 M allocated; HK$0.65 M used by 30 Jun 2026)Largely unexecuted; HK$4.99 M unutilisedIRA H1 2026
FY2025Feasibility of digital ID photo output via boothsUnder assessment; no launch disclosedARA FY2025
Dec 2025Discontinue Guangdong booth expansion; concentrate on Hong KongCompleted (subsidiary deregistered)ARA FY2025
Dec 2025Discontinue planned medical laboratory expansionCompletedARA FY2025
FY2024–FY2025Cost reduction (staff, directors' remuneration)Admin costs −18% FY2025; −23% H1 2026 YoYARA FY2025; IRA H1 2026
8 Aug 2025Workforce Diversity PolicyAdoptedAR 2025
25 Sep 2026Extension of doctor service agreements (Echo Bay, Mingway) to 31 Dec 2028 with increased annual capsExecutedAnnouncement 25 Sep 2026

New controller's stated intentions (JA 27 Jul 2026)

The offeror stated that the Group will continue its existing photography and medical businesses after the offer and maintain the GEM listing; that it will review operations and financial position to devise plans and explore opportunities; that it has no intention to discontinue employees (other than board changes) or redeploy fixed assets outside the ordinary course, while reserving the right to make changes after its review. Mr. Li characterised the investment as a new venture into the Group's principal businesses. Given Mr. Li's F&B background and the new executive director's PRC capital-markets compliance experience, investors should watch for new business injections or acquisitions — none has been announced as of 11 October 2026.

Medium-term targets / guidance

No medium-term financial targets, revenue guidance or margin targets have been published by either legacy or current management. ESG/sustainability targets: none quantitative disclosed in reviewed filings.

Products & Services

Photography Services

OfferingDescriptionKey capabilitiesTarget customerLaunch / latestPricing modelSource
Max Sight Photo automatic ID photo booths (Hong Kong)Self-service digital booths producing ID photos to multiple official specificationsMultiple ID specifications (passport, HKID, visa, permits); high-end print quality; validation against specifications; smart-card paymentGeneral publicBrand operating since 1989; digital booths since c. late 1990s–2003Per-session retail price (specific tariffs not disclosed in filings)Company website; IRA H1 2026; AR 2025
"Unconditional guarantee"Free retake or full refund on return of unsatisfactory photosService-quality differentiatorGeneral publicOngoingIncludedCompany website
Photo strip sales to institutional customerAfter April 2025 expiry of a service contract at multiple ID/visa application centres, Group retained the customer by selling strips (consumables) instead of providing full serviceSupply of consumablesGovernment-linked ID/visa centresFrom April 2025Per-strip product pricing, materially lower unit value than prior service modelIRA H1 2026; ARA FY2025
Automatic photographic studio services at government ID offices24-month tender won Feb 2023, effective 1 Mar 2023, for a HK government authority responsible for issuing ID documentsInstalled booth/studio services in government officesHK government authority2023–2025Tender contract (value not disclosed)AR 2023
名仕富美 booths (Guangdong)ID photo booths in Guangdong provinceAs abovePRC public2005–2025Per-sessionAR 2023; AR 2025
Digital ID photo services via booths (under study)Feasibility assessment of offering digital ID photo outputs through existing boothsDigital file deliveryPublic applying onlineUnder evaluation (FY2025)—ARA FY2025

Medical Services ("Max Medical 名仕醫療")

OfferingDescriptionTarget customerLaunchPricing modelSource
General practice consultationsDiagnosis and treatment of acute illness, chronic disease managementWalk-in patients; medical-card membersOct 2021Fee-for-service; medical card settlement via network agents within ~60 daysIRA H1 2026
Vaccinations (incl. seasonal influenza)Vaccine administrationGeneral public, elderly2021 onwardFee-based; government vouchers acceptedARA FY2025; company website
Health screening / physical exam plansMultiple-choice physical examination packagesIndividuals, corporates—Package pricing (not disclosed)Company website
Specialist referralsReferral to specialistsPatients—Included in consultationIRA H1 2026
Outreach doctor servicesDoctor visits outside clinics———Company website
Therapeutic services and wellness merchandiseRetail of therapeutic/wellness productsPatients—RetailCompany website
Community medical benefit programmeCSR programmeCommunity—SubsidisedCompany website

Clinic locations disclosed: Wong Tai Sin (Max Medical Service Limited; doctor services by Echo Bay / Dr. Li Ka Hei Calvin) and Sham Shui Po (Wealthy Dragon; doctor services by Mingway / Dr. Tse Ming) (announcement 25 Sep 2026). A new medical centre tenancy was signed in FY2023 (AR 2023). The total number of clinics is not explicitly stated in the filings reviewed.

Abandoned initiatives: Medical laboratory expansion (discontinued Dec 2025 due to price competition from Mainland labs) and new clinic acquisitions (none identified in FY2025 or H1 2026) (ARA FY2025; IRA H1 2026).

Financial Narrative

Income statement

Sources and notes: FY2024–FY2025 from ARA FY2025. FY2022–FY2023 revenue, cost of services, gross profit, admin, finance costs, tax and attributable result from AR 2023. FY2023 and FY2022 operating profit and PBT are (derived) from AR 2023 line items (FY2023: GP 26.905 + other income 0.584 − other net losses 0.049 − admin 18.273 − ROU impairment 0.077; FY2022 uses an ROU impairment of approx. HK$2.1 M from the 7 Mar 2023 profit warning). FY2021 and FY2022 net loss (approx.) from profit warnings (FY2021 approx. HK$7.7 M; FY2022 approx. HK$12.4 M). FY2023 net profit approx. HK$8.0 M (derived), consistent with the positive profit alert indicating not less than HK$8 M. EPS for FY2022–FY2023 (derived) on 800 M shares. FY2023 DPS = interim HK$0.00375 + special HK$0.005625. EBITDA is post-HKFRS 16 (includes right-of-use depreciation, so it overstates cash earnings).

Margins and growth

Revenue CAGR FY2021–FY2025: approx. +20.7% per year (distorted by the COVID trough base). Revenue CAGR FY2023–FY2025: approx. −25.5% per year (derived). FY2021 growth uses FY2020 revenue of approx. HK$19.98 M (profit warning 4 Mar 2021; TipRanks).

Interim trend: notes and sources

Source: IRA H1 2025; IRA H1 2026.

Balance sheet

Sources: ARA FY2025; AR 2023; IRA H1 2025 (opening equity 1 Jan 2024). FY2022 and FY2023 total assets (derived) from reported equity and gearing ratio (total liabilities ÷ total assets of 51.5% and 48.7%). No goodwill or intangibles appear on the FY2024–FY2025 statements of financial position.

At 30 June 2026: total assets HK$29.455 M; cash HK$9.206 M; lease liabilities HK$12.086 M; total equity HK$12.551 M (attributable HK$11.444 M); net current assets HK$2.455 M (IRA H1 2026).

Cash flow

Interim operating cash flow (table 6.3) shows a sharp deterioration from HK$6.3 M (H1 2024) to HK$1.4 M (H1 2026); after lease principal and interest payments of HK$4.7 M in H1 2026, lease-adjusted free cash flow was approximately −HK$3.3 M for the half (derived from IRA H1 2026). Sources: AR 2023; ARA FY2025; IRA H1 2025; IRA H1 2026.

Ratios

Current, quick and gearing ratios as reported (AR 2023; ARA FY2025). Other ratios (derived). ROIC and cash conversion cycle: not meaningfully computable from disclosed data (no invested-capital disclosure; business is largely cash-settled with receivables of HK$1.8 M at FY2025, i.e., roughly 15 days of revenue — derived). Net debt/EBITDA FY2025 approx. 0.2x including leases (derived).

Commentary on trends, inflections and drivers

Revenue. The five-year arc is defined by three phases. FY2020–FY2022 was a COVID trough in which travel-document demand collapsed and the Group launched medical services as a hedge, lifting FY2022 revenue 49% on the first full year of clinic operations (AR 2022 summary). FY2023 was an exceptional reopening spike — photography revenue rose 178% as quarantine was lifted and travel resumed, and a two-year government-site tender began in March 2023 (AR 2023). FY2024–FY2026 is a structural decline: photography revenue fell 51% in FY2025 and another 53% in H1 2026 as the government contract matured (April 2025), the Immigration Department's PDSK kiosks absorbed demand, e-visas reduced physical photo needs, and immigration-scheme tailwinds (JoyYou card from 2022; Top Talent Pass Scheme) proved less durable than expected (ARA FY2025).

Margins. Gross margin peaked at 33.5% in FY2023 and has compressed to 25.2% in H1 2026 because photography carries a higher margin than medical and its share of the mix has fallen (ARA FY2025). Variable lease payments to booth landlords fell from HK$17.2 M (FY2024) to HK$4.6 M (FY2025), showing that much of the photography cost base was revenue-linked, which cushioned but did not prevent margin erosion (ARA FY2025 note 7).

Costs. Management cut administrative expenses by 18% in FY2025 and a further 23% year-on-year in H1 2026, mainly through staff reductions (headcount down from 78 to 45 in 30 months) and lower directors' remuneration (ARA FY2025; IRA H1 2026). Head-office costs remain disproportionate: HK$8.7 M of corporate expenses in FY2025 against total segment profit of HK$4.6 M — the listed-company overhead alone exceeds what the operations earn.

Balance sheet. The company carried no bank debt at end-2024 and end-2025, but equity has nearly halved from HK$28.7 M (attributable, 1 Jan 2024) to HK$11.4 M (30 Jun 2026) through a combination of losses and HK$9.3 M of special dividends paid in 2024–2025 out of share premium and distributable reserves. Distributable reserves of the company were just HK$165k at end-2025 (AR 2025), effectively precluding further dividends. Cash has fallen from HK$25.7 M (end-2023) to HK$9.2 M (mid-2026), while lease obligations (HK$12.1 M) now exceed cash — the group has swung from net cash to modest net debt on a lease-inclusive basis.

Inflection. H1 2026 is the first period in which both segments declined simultaneously (medical revenue −10.7% due to an absent winter influenza season and a new price-competitive clinic near one of the Group's sites) (IRA H1 2026). At the current burn rate, liquidity is adequate for perhaps 18–24 months absent action, but the trajectory explains the founders' decision to exit.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProducts / servicesStatus

Photography services — Hong Kong

Max Sight Limited and related entities; booth network across MTR stations, ID/visa centres, malls, universities, hospitals

Self-service ID photo booths; sale of photo strips to an institutional customer at ID/visa centres

Core, declining

Photography services — Mainland China

Guangzhou Max Sight Photo Company Limited ("名仕富美" brand)

ID photo booths in Guangdong

Effectively discontinued; revenue HK$9k in FY2025, nil in H1 2026; subsidiary deregistered in FY2025

Medical services — Hong Kong

Max Medical Service Limited, Max Sight Healthcare Management Limited, Speed Dragon Development Limited (81%), Wealthy Dragon Development Limited (80%), Max Medical Service (NOP Clinic) Limited

GP consultations, vaccinations, health screening, specialist referrals, wellness merchandise

Largest segment from FY2025

Photography

21.1810.00921.190

Medical

23.305023.305

Total

44.4860.00944.495

Revenue by Segment

SegmentFY2021FY2022FY2023FY2024FY2025

Photography services Hong Kong (HKD Mn)

18.9722.4263.8342.49821.181

Photography services Mainland China (HKD Mn)

1.340.941.210.9170.009

Medical services Hong Kong (HKD Mn)

0.6427.89115.17922.83123.305

Total revenue (HKD Mn)

20.95331.25380.21866.24644.495

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment

SegmentFY2024FY2025

Photography Hong Kong segment profit (HKD Mn)

12.3973.112

Photography Mainland China segment profit (HKD Mn)

0.145-0.316

Medical Hong Kong segment profit (HKD Mn)

1.1671.758

Total reportable segment profit (HKD Mn)

13.7094.554

Head office and corporate expenses (HKD Mn)

-12.977-8.690

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2021FY2022FY2023FY2024FY2025

Photography HK segment margin (%)

———29.214.7

Medical HK segment margin (%)

———5.17.5

Photography HK revenue growth YoY (%)

—18.2184.7-33.4-50.2

Medical HK revenue growth YoY (%)

—1,129.192.450.42.1

Photography (all) share of revenue (%)

96.974.881.165.547.6

Medical share of revenue (%)

3.125.218.934.552.4

Revenue by Segment (Half-Yearly)

SegmentH1 2024H1 2025H1 2026

Photography HK revenue (HKD Mn)

22.88714.2556.646

Photography Mainland revenue (HKD Mn)

0.5540.0090

Medical HK revenue (HKD Mn)

11.13311.88410.609

Photography HK segment profit (HKD Mn)

6.9083.9640.290

Medical HK segment profit (HKD Mn)

0.4561.2820.778

Group Entities

EntityJurisdictionFunctionOwnershipSource

Max Sight Limited

Hong Kong

Original photo-booth operator (since 1989)

100% (indirect)

AR 2023/2025

Fullwise International Limited

Not disclosed in reviewed docs

Group holding/operating entity

—

AR 2023

Guangzhou Max Sight Photo Company Limited

PRC

Guangdong booth operator

Deregistered FY2025 (inferred from deregistration loss and nil Mainland activity)

AR 2023; ARA FY2025

Max Medical Service Limited

Hong Kong

Medical services; Wong Tai Sin clinic

100%

Announcement 25 Sep 2026

Max Sight Healthcare Management Limited

Hong Kong

Clinic management services

100%

Announcement 25 Sep 2026

Speed Dragon Development Limited

Hong Kong

Clinic-holding subsidiary

81% (Echo Bay holds 19%)

Announcement 25 Sep 2026

Wealthy Dragon Development Limited

Hong Kong

Sham Shui Po clinic

80% (Mingway holds 20%)

Announcement 25 Sep 2026

Max Medical Service (NOP Clinic) Limited

Hong Kong

Medical (formerly MV Asset Management Limited)

Not disclosed in reviewed docs

AR 2025

“—” = not publicly disclosed.

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (HKD Mn)

20.95331.25380.21866.24644.495

Cost of services (HKD Mn)

—26.17553.31345.96932.426

Gross profit (HKD Mn)

—5.07826.90520.27712.069

Administrative expenses (HKD Mn)

—16.59618.27319.21915.691

Operating profit / loss from operations (HKD Mn)

—-12.109.091.434-3.147

Depreciation total (HKD Mn)

———9.93810.300

EBITDA incl. ROU depreciation (HKD Mn)

———11.3727.153

Finance costs (HKD Mn)

—0.4540.6590.7021.053

Profit / loss before tax (HKD Mn)

—-12.558.430.732-4.200

Income tax (expense negative) (HKD Mn)

—0.120-0.412-0.2620.237

Net profit / loss for year (HKD Mn)

-7.7-12.48.00.470-3.963

Attributable to owners (HKD Mn)

—-11.5187.658-0.399-4.598

Basic and diluted EPS (HK cents)

—-1.440.96-0.05-0.57

Dividends per share declared for the year (HK cents)

—00.93750.600

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue growth YoY (%)

4.949.2156.7-17.4-32.8

Gross margin (%)

—16.2533.5430.627.1

Operating margin (%)

—-38.711.32.2-7.1

EBITDA margin (%)

———17.216.1

Net margin (%)

-36.7-39.710.00.7-8.9

Cash Flow and Margin Analysis (%)

MetricH1 2024H1 2025H1 2026

Revenue (HKD Mn)

34.57426.14817.255

Gross profit (HKD Mn)

10.8398.2184.347

Gross margin (%)

31.3531.4325.19

Administrative expenses (HKD Mn)

10.1888.7536.744

Profit / loss from operations (HKD Mn)

0.739-0.152-2.335

Profit / loss attributable to owners (HKD Mn)

-0.199-1.138-3.255

Net cash from operating activities (HKD Mn)

6.2924.6841.400

Balance Sheet

MetricFY2022FY2023FY2024FY2025

Total assets (HKD Mn)

46.854.545.81035.898

Cash and bank balances (HKD Mn)

21.69925.66921.32012.902

Restricted bank deposit (HKD Mn)

5.05.000

Bank loans (HKD Mn)

1.01.000

Lease liabilities current (HKD Mn)

——6.8197.949

Lease liabilities non-current (HKD Mn)

——8.0736.549

Total lease liabilities (HKD Mn)

——14.89214.498

Net debt incl. leases (HKD Mn, negative = net cash)

——-6.4281.596

Total equity (HKD Mn)

22.71427.94524.16315.462

Equity attributable to owners (HKD Mn)

—28.68624.03514.699

Goodwill and intangibles (HKD Mn)

——00

Net current assets (HKD Mn)

——13.6295.021

Right-of-use assets (HKD Mn)

——13.92813.574

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Capital expenditure on PP&E (HKD Mn)

—3.0000.5721.7150.016

Dividends paid (HKD Mn)

—03.0004.5004.800

Share buybacks (HKD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025

ROE on average total equity (%)

—31.71.8-19.9

ROE attributable on average attributable equity (%)

——-1.5-23.7

ROA on average total assets (%)

—15.80.9-9.7

Current ratio (x)

1.921.952.041.37

Quick ratio (x)

1.871.871.921.24

Gearing total liabilities / total assets (%)

51.548.747.356.9

Lease liabilities to equity (x)

——0.620.94

Interest coverage EBIT / finance costs (x)

—13.82.0-3.0

Asset turnover (x)

—1.581.321.09

Revenue by Region

RegionFY2021FY2022FY2023FY2024FY2025

Hong Kong (HKD Mn)

19.6230.3179.0165.32944.486

Mainland China (HKD Mn)

1.340.941.210.9170.009

Region Margins & Growth (%)

RegionFY2022FY2023FY2024FY2025

Hong Kong revenue growth (%)

54.5160.7-17.3-31.9

Mainland China revenue growth (%)

-29.928.7-24.2-99.0

Share Price History

DatePrice (HKD)ContextSource

28 Feb 2018

0.31 (offer) / 0.36 (day-1 close)

IPO

Press release 28 Feb 2018

~25 Apr 2024

0.084

Pre-FY2024 results

Yahoo Finance snapshot

~22 Oct 2025

approx. 0.097

Market cap HK$77.6 M on Simply Wall St

Simply Wall St (derived)

16 Feb 2026

0.093

Six-month closing low

JA 27 Jul 2026

5 May 2026

0.146

Six-month closing high

JA 27 Jul 2026

24 Jul 2026

0.112

Last trading day before SPA

JA 27 Jul 2026

Offer price

0.0875

SPA and mandatory offer price

JA 27 Jul 2026

~5 Oct 2026

0.33

Approx. +177% year-to-date per MarketScreener

MarketScreener; Yahoo Finance

Valuation Snapshot

MultipleValueBasis

Market cap

approx. HK$264 M

800 M × 0.33

Enterprise value (incl. leases)

approx. HK$267 M

264 − cash 9.2 + leases 12.1

TTM revenue

HK$35.6 M

FY2025 44.495 − H1'25 26.148 + H1'26 17.255

TTM attributable net loss

−HK$6.7 M

−4.598 + 1.138 − 3.255

P/E

Not meaningful (loss)

—

EV/Sales

approx. 7.5x

—

EV/EBITDA (post-HKFRS 16)

approx. 61x

TTM EBITDA approx. HK$4.4 M (derived)

P/B

approx. 23x

Attributable equity HK$11.4 M

Offer-implied valuation

HK$70 M equity; approx. 4.8x NAV

JA 27 Jul 2026

Per-Share Data and Dividends & Capital Returns

MetricFY2022FY2023FY2024FY2025

DPS declared in respect of year (HK cents)

00.93750.600

Total dividends declared (HKD Mn)

07.54.80

Analyst Conclusions

Management guidance and consensus

No quantitative guidance has been issued by legacy or new management, and there is no sell-side consensus. The legacy board's last outlook (FY2025 AR) was "cautiously optimistic," premised on persistent ID-photo demand and policy tailwinds in primary care. The new controller has committed only to continuing existing businesses, maintaining the listing and conducting a review (JA 27 Jul 2026).

Bull case

  1. Platform optionality under a funded new owner. CWT paid HK$52.5 M in cash with no borrowings, and the chairman has multi-country F&B and tech investment experience; asset injections or acquisitions could transform scale relative to a HK$12.6 M equity base (JA 27 Jul 2026).

  2. Medical segment stabilisation plus policy tailwind. Medical revenue held at HK$22–23 M through FY2024–FY2025 and doctor agreements are locked in to 2028 with rising caps; a normal flu season and HA fee reform could restore growth (announcement 25 Sep 2026; IRA H1 2026).

  3. Lean cost base post-restructuring. Headcount down 42% since 2023 and admin costs down sharply; a cleaner, Hong Kong-only operation with no bank debt lowers break-even (IRA H1 2026).

Bear case

  1. Core business in terminal decline. Photography HK segment profit is down 96% in two years and the drivers (PDSK, e-visas, expired contract) are structural, not cyclical (IRA H1 2026).

  2. Valuation detached from fundamentals. At approx. 23x book and 7.5x sales for a loss-making company, the share price embeds substantial speculative value, nearly 4x the price the controller paid weeks earlier, on a sub-minimum free float (derived; JA 2 Oct 2026).

  3. Cash runway and governance discontinuity. Cash HK$9.2 M against lease obligations of HK$12.1 M and an H1 2026 lease-adjusted cash burn of approx. HK$3.3 M; entire experienced management departed, with no CEO named (IRA H1 2026; announcement 5 Oct 2026).

Catalysts and monitorables (next 12 months)

CatalystExpected timingWhat to watch
Public float restoration (placing down by CWT) and Stock Exchange waiverQ4 2026Placing price vs. market; risk of suspension
CEO appointment and executive team compositionQ4 2026Operating continuity of booth and clinic businesses
Offeror's strategic review outcome; any acquisition or asset injectionQ4 2026 – 2027Related-party nature, valuation, any equity issuance/dilution
Use of remaining HK$7.35 M IPO proceeds by 31 Dec 2026By Dec 2026Possible further reallocation
ME Group supply relationship post-MSA expiry2026–2027Renewal, alternative suppliers
FY2026 profit warning / resultsMar 2027Revenue trajectory; second-half influenza season impact on medical
Auditor continuity (RSM Hong Kong) and any going-concern commentaryMar 2027Audit opinion

Analyst verdict

Max Sight Group is no longer primarily an operating story; it is a change-of-control story wrapped around a shrinking legacy business. The fundamentals are unambiguous. The photo-booth franchise that sustained the company for over three decades is being hollowed out by government digitisation — Hong Kong photography segment profit fell from HK$12.4 million in FY2024 to under HK$0.3 million in the first half of 2026 — and the medical diversification, though steady at roughly HK$22–23 million of revenue, is too small and too low-margin to carry a listed-company overhead that by itself exceeds total segment earnings. Equity has more than halved in 30 months through losses and special dividends, distributable reserves are exhausted, and lease obligations now exceed cash.

Against this backdrop, the founders' decision to sell 75% at HK$0.0875 per share — a discount to market but nearly five times book value — is rational, and it crystallised what the platform was worth to a strategic buyer. The subsequent re-rating to around HK$0.33 is not supported by any disclosed operating improvement; it reflects speculation about what Mr. Li Xiangpu will do with a GEM-listed vehicle, amplified by a public float that has slipped below the regulatory minimum.

For fundamental investors, the risk-reward at current prices is unfavourable: the downside if no value-accretive transaction materialises is substantial, with intrinsic value anchored closer to the offer price and net assets than to the current quote. For special-situation investors, the critical near-term variables are the terms of any float-restoring placement, the identity and track record of incoming management, and whether any injected business is acquired at arm's-length value without heavy dilution. Until the new controller articulates a credible plan, Max Sight should be regarded as a high-risk, event-driven shell-adjacent situation rather than an investable operating franchise.


Primary sources referenced

  • Max Sight Group — Annual Results Announcement FY2025 (23 Mar 2026), hkexnews.hk

  • Max Sight Group — Annual Report 2025 (2 Apr 2026) and Annual Report 2023 (28 Mar 2024), maxsightgroup.com

  • Max Sight Group — Interim Results Announcements H1 2025 (8 Aug 2025) and H1 2026 (31 Aug 2026)

  • Joint Announcement — SPA and Mandatory Unconditional Cash Offer (27 Jul 2026)

  • Joint Announcement — Close of Offer, Results and Public Float (2 Oct 2026)

  • Announcement — Continuing Connected Transactions: Echo Bay and Mingway Service Agreements (25 Sep 2026)

  • Announcement — Resignation and Appointment of Directors (5 Oct 2026); company website board biographies

  • Profit warnings dated 4 Mar 2021, 4 Mar 2022, 7 Mar 2023, 14 Mar 2025 (hkexnews.hk)

  • Company press releases on IPO (15, 27 and 28 Feb 2018)

  • Third-party data: MarketScreener (segment history FY2021–FY2023, price), Yahoo Finance (price, TTM), Simply Wall St (Oct 2025 ownership/market cap), TipRanks (revenue history, peer list), Morningstar (company profile)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackgroundEducationAge

Mr. Li Xiangpu (李相璞)

Executive Director, Chairman; Chair of Nomination Committee; member of Remuneration Committee; authorised representative

5 Oct 2026

Entrepreneur with close to 15 years' experience in VC, IT and internet businesses; since 2017 invested in/managed F&B businesses (fast-food chains, restaurants, foodstuff supply chains) in HK, PRC, Indonesia, Vietnam and Korea; previously Testing Manager at Nokia (2008–2012) and Senior Engineer at Lucent Technologies (2004–2008); sole director and ultimate controller of CWT Limited

B.Eng. electronic science and technology (2004) and M.Eng. (2011), Beijing University of Posts and Telecommunications

44 (per JA 27 Jul 2026)

Mr. Yang Lichao (楊立超)

Executive Director

5 Oct 2026

15+ years in finance management and compliance; former strategy director and board secretary of Shanghai Fukong Interactive Entertainment (former SSE: 600634, delisted Jul 2021); compliance director of Shanghai Banxiaoyao Technology since Jul 2023; prior finance roles at several PRC industrial groups

Bachelor of Management, Anhui University of Technology (2008); SSE board secretary qualifications

—

Mr. Zhong Jin (鍾錦)

Lead INED; Chair of Remuneration Committee; member of Audit and Nomination Committees

5 Oct 2026

40+ years in banking/finance; China Construction Bank Sichuan roles (1985–2002); China CINDA Asset Management office director (2002–2011); MD then chairman of China CINDA (Hong Kong) Holdings (2011–2019); INED of Luzhou Bank (01983) since Nov 2020

PhD Finance, Southwestern University of Finance and Economics (2006); senior economist

—

Mr. Pang Peter Chun Ming (彭浚銘)

INED; Chair of Audit Committee; member of Remuneration Committee

5 Oct 2026

20+ years in audit and finance; Ernst & Young (US/HK); BOCI Asia corporate finance; Deutsche Bank; CFO of Renjian Antong, Pa Shun Pharmaceutical (00574) and Fuli Peridot Mining; currently CFO of Neo-Concept International (NASDAQ: NCI) and INED of Zuoli Kechuang (06866)

BA Economics UC Berkeley; MAcc USC; California CPA; CFA

—

Ms. Sze Tak On (施得安)

INED; member of Audit and Nomination Committees

5 Oct 2026

Financial controller (since 2004) and company secretary of Century Legend (Holdings) (00079); INED of A.Plus Group (01841), Prosperous Industrial (01731), China Starch (03838)

MCF, Hong Kong Polytechnic University; HKICPA, FCCA, HKCGI

—

“—” = not publicly disclosed.

Board of Directors — Mr. Chan Wing Chai, Jamson

NameRoleTenureNotes

Mr. Chan Wing Chai, Jamson

Chairman, ED

26 Jan 2017 – 5 Oct 2026 (Group director since 1989)

Age 79 (AR 2025); founder; expected to remain director of subsidiaries post-deal (JA 27 Jul 2026)

Mr. Chan Tien Kay, Timmy

CEO, ED, compliance officer

26 Jan 2017 – 5 Oct 2026

Age 52; Queensland solicitor; son of Jamson Chan; expected to remain director of subsidiaries

Dr. Chan Wing Lok, Brian

ED; chief medical executive

6 Sep 2021 – 23 Mar 2026

Age 61; ex-ED of Town Health International (3886); resigned due to personal health (AR 2025)

Mr. Riccardo Costi

NED

26 Jan 2017 – 5 Oct 2026

Age 81; associate interested in Dedem S.p.A. (European photo-booth operator) — declared competing interest

Ms. Wong Shin Yee, Freda

NED

8 Nov 2024 – 5 Oct 2026

Age 55; managing partner, Sunny Fortune Capital

Mr. Ngai James

INED, Lead INED, Audit and Remuneration chair

8 Feb 2018 – 5 Oct 2026

CPA; chairman of Le Saunda Holdings (0738)

Mr. Hui Chi Kwan

INED

8 Feb 2018 – 5 Oct 2026

Solicitor; INED of Le Saunda

Mr. Kwok Tsun Wa

INED

8 Feb 2018 – 5 Oct 2026

Insurance veteran (Lombard, HSBC Non-Life, Marsh HK)

Directors' Remuneration

MetricFY2024FY2025

Key management remuneration total (HKD Mn)

7.5286.921

Of which short-term benefits (HKD Mn)

7.4096.813

Board & Management Changes

DateChangeContext

23 May 2024

Zhu Yulin appointed finance director

Replaced Wong Chi Hong's finance role (AR 2025)

8 Nov 2024

Wong Shin Yee, Freda appointed NED

Addressed single-gender board commitment by end-2024 (AR 2023)

8 Aug 2025

Wong and Hui added to Nomination Committee; Workforce Diversity Policy adopted

Governance enhancements (AR 2025)

23 Mar 2026

Dr. Brian Chan resigns as ED

Personal health (AR 2025)

23 Sep 2026

Board resolves to appoint Li, Yang, Zhong, Pang, Sze effective 5 Oct 2026

Post-takeover reconstitution

5 Oct 2026

All seven legacy directors resign; Li appointed chairman; Zhong lead INED

Required under SPA (JA 27 Jul 2026)

Major Shareholders

HolderShares%Source

CWT Limited (99% XDQX ZZRS Ltd / XPFF Trust; 1% BTY PT Ltd — all ultimately Li Xiangpu and family)

601,144,00075.14

JA 2 Oct 2026

Public shareholders

198,856,00024.86

JA 2 Oct 2026

Total

800,000,000100.00—

Competitive Landscape

Competitors by Segment

SegmentCompetitor / substituteTypePositioning vs. Max Sight

ID photography

HK Immigration Department Personal Document Submission Kiosks (PDSK)

Government digital substitute (free digital photo capture during submission)

Most damaging substitute; company attributes approx. 19% same-site strip-volume decline in H1 2026 to PDSK

ID photography

Traditional photo studios (notably near visa application centres)

Fragmented SMEs

Persistent price competition cited every period since 2024

ID photography

Smartphone/e-visa digital photo submission

Behavioural substitute

Structural demand erosion

ID photography

Other HK booth operators

Not identified in filings

Company claims leading booth operator position

ID photography (global)

ME Group International plc (Photo-Me)

Global booth operator/manufacturer; former 13.75% shareholder and supplier

Not a direct HK competitor; strategic supplier

ID photography (Europe)

Dedem S.p.A.

European booth operator linked to former NED Riccardo Costi's associate

Declared potentially competing business; no HK overlap disclosed

Primary care

Town Health International Medical Group (HKEX: 3886)

Listed HK medical network

Far larger network; Dr. Brian Chan's former employer

Primary care

UMP Healthcare Holdings (HKEX: 722)

Listed HK corporate healthcare network

Larger scale, corporate-contract focus

Primary care

Human Health Holdings (HKEX: 1419)

Listed HK GP and specialist clinics

Larger GP network

Primary care

Modern Healthcare Technology Holdings; Miricor Enterprises; Sino-Life Group; Anxian Yuan China (listed peers per TipRanks peer screen)

Listed small-cap HK health/consumer services

Similar micro-cap scale

Primary care

Hospital Authority general out-patient clinics

Public provider

Lower-cost alternative; fee reform from 2026 may shift non-urgent demand to private sector

Primary care

Independent private GPs (incl. a new price-competitive clinic near one Group site)

Fragmented

Cited as driver of H1 2026 medical revenue decline

Competitor Detail

MetricMax Sight (FY2025)

Revenue

HK$44.5 M

Revenue growth

−32.8%

Gross margin

27.1%

Net margin

−8.9%

Recent Developments

--

Company Snapshot

$5.7M

Revenue

45

Employees

1989

Founded

P.O. Box, Cayman Islands

Headquarters

SWOT Analysis

Strengths

  • No bank borrowings: Nil bank loans at 31 Dec 2024, 31 Dec 2025 and 30 Jun 2026 (ARA FY2025; IRA H1 2026)
  • Medical revenue resilience through FY2025: Medical revenue grew from HK$0.6 M (FY2021) to HK$23.3 M (FY2025) and rose 2.1% in FY2025 despite a weak flu season (ARA FY2025)
  • Customer retention capability: Retained the government ID/visa-centre customer after the April 2025 contract maturity by switching to strip sales (IRA H1 2026)
  • Prime booth site portfolio: Licensed locations cover most metro stations, ID/visa centres, selected malls and universities (IRA H1 2026)
  • Variable cost structure in photography: Variable lease payments fell from HK$17.2 M to HK$4.6 M in FY2025 as revenue fell, protecting margins (ARA FY2025)
  • Demonstrated cost discipline: Admin expenses cut 18% in FY2025 and 23% YoY in H1 2026; headcount 78 → 45 (ARA FY2025; IRA H1 2026)
  • Doctor-aligned clinic model: Doctor partners hold 19–20% of clinic subsidiaries and share profits; agreements extended to end-2028 (announcement 25 Sep 2026)

Weaknesses

  • Collapsing core profitability: Photography HK segment profit fell from HK$12.4 M (FY2024) to HK$3.1 M (FY2025) and HK$0.29 M (H1 2026)
  • Overhead exceeds operating profit: Head-office expenses HK$8.7 M vs. segment profit HK$4.6 M in FY2025 (ARA FY2025)
  • Eroding equity base: Attributable equity fell from HK$28.7 M (1 Jan 2024) to HK$11.4 M (30 Jun 2026)
  • Thin distributable reserves: Company distributable reserves only HK$165k at end-2025 (AR 2025)
  • Liquidity tightening: Cash HK$25.7 M (end-2023) → HK$9.2 M (mid-2026); current ratio 2.04 → 1.21 (AR 2023; IRA H1 2026)
  • Failure to deploy expansion capital: HK$4.99 M of medical-development proceeds unutilised at 30 Jun 2026; no new clinic since FY2023 (IRA H1 2026)
  • Supplier concentration: Five largest suppliers 68% of purchases; largest 22% (ARA FY2025)

Opportunities

  • Hospital Authority fee reform: Effective 1 Jan 2026; non-urgent A&E cases down approx. 22% in H1 2026 (IRA H1 2026)
  • Primary Healthcare Blueprint: Government policy direction favouring community primary care (ARA FY2025)
  • Digital ID photo services via booths: Feasibility under assessment (ARA FY2025)
  • New controller's capital and network: CWT paid HK$52.5 M in cash from internal resources (JA 27 Jul 2026) — signals capacity for further investment
  • Listing platform value: Offer price implied a 376% premium to NAV (JA 27 Jul 2026) — platform can be used for asset injections or acquisitions
  • Influenza normalisation: H1 2026 medical decline driven by absent flu season; reversion could restore volumes (IRA H1 2026)

Threats

  • Government digitisation of ID photos: PDSK adoption → approx. 19% same-site strip-volume decline in H1 2026 (IRA H1 2026)
  • Price competition in both segments: Traditional studios near visa centres; new clinic competitor near a Group site (IRA H1 2026)
  • Public float breach: Float 24.86% vs. 25% minimum; Stock Exchange may suspend trading if not restored (JA 2 Oct 2026)
  • Strategic discontinuity: Entire board and founding management departed 5 Oct 2026; no CEO designated (announcement 5 Oct 2026)
  • Doctor dependency: Business model relies on consultancy arrangements terminable on notice (AR 2025 risk factors)
  • Site licence renewal risk: Booth and clinic premises depend on licence/lease renewals (AR 2025 risk factors)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Major government ID/visa-centre service contract matures; converted to sale of strips ARA FY2025; IRA H1 2026Single largest driver of FY2025–H1 2026 photography revenue collapse; related gross profit −60%
19–20 May 2025Trading halt in the shares MarketScreener news logLinked to change-of-control discussions
22 May 2025Special dividend HK$0.006/share (HK$4.8 M) declared from distributable reserve IRA H1 2025Final material cash return; depleted distributable reserves
23 Jun 2025Special dividend paid IRA H1 2025Cash fell to HK$15.2 M by 30 Jun 2025
4 Jul 2025MOU for possible sale of Causeway Treasure's shares lapses IRA H1 2025First failed exit attempt
8 Aug 2025H1 2025 results: revenue −24.4% to HK$26.1 M; attributable loss HK$1.1 M IRA H1 2025Losses emerge
8 Aug 2025Workforce Diversity Policy adopted; Nomination Committee expanded AR 2025Governance
1 Nov 2025Original Mingway service agreement (Sham Shui Po clinic) signed Announcement 25 Sep 2026Doctor continuity
19 Dec 2025Change in use of IPO proceeds; Guangdong and laboratory plans formally discontinued ARA FY2025Strategic retrenchment to HK
29 Dec 2025Hospital Authority announces public fee reform effective 1 Jan 2026 ARA FY2025Potential tailwind for private primary care
6 Mar 2026Profit warning: FY2025 net loss after tax expected not to exceed HK$4 M MarketScreener news log; company announcements listPre-announcement
23 Mar 2026FY2025 results: revenue −32.8% to HK$44.5 M; attributable loss HK$4.6 M; no dividend ARA FY2025Confirms structural decline
23 Mar 2026Dr. Brian Chan resigns as ED (health) AR 2025Loss of medical leadership
2 Apr 20262025 Annual Report published; AGM notice Company websiteRoutine
17 Apr 2026Original Echo Bay service agreement (Wong Tai Sin clinic) signed Announcement 25 Sep 2026Doctor continuity
12 Jun 2026AGM held; poll results published Company websiteRoutine
26 Jul 2026SPA signed: CWT Limited to buy 75% at HK$0.0875/share; deed of indemnity from Jamson Chan and Causeway Treasure JA 27 Jul 2026Change of control
27 Jul 2026Trading halt; completion of SPA; joint announcement of mandatory offer JA 27 Jul 2026Founders, ME Group and Cheung exit
28 Jul 2026Trading resumes Company website–
31 Jul 2026Independent financial adviser appointed (Red Sun Capital, per composite document consent letter) Company websiteTakeovers Code process
11 Aug 2026Profit warning for H1 2026 Company websitePre-announcement
17 Aug 2026Delay in despatch of composite document announced Company websiteProcess
31 Aug 2026H1 2026 results: revenue −34.0% to HK$17.3 M; attributable loss HK$3.3 M; both segments decline IRA H1 2026Deterioration accelerates
11 Sep 2026Composite offer document despatched Company websiteOffer opens
18 Sep 20262026 Interim Report published Company websiteRoutine
23 Sep 2026Board approves appointment of new EDs and INEDs effective 5 Oct 2026 Announcement 5 Oct 2026Board transition
25 Sep 2026Continuing connected transactions: Echo Bay and Mingway agreements extended to end-2028 with higher caps Announcement 25 Sep 2026Medical cost visibility; new-board continuity signal
2 Oct 2026Offer closes: 4 acceptances for 1,144,000 shares; CWT at 75.14%; public float 24.86% — below 25%; waiver to be sought JA 2 Oct 2026Float restoration required (placing down likely)
5 Oct 2026Entire legacy board resigns; Li Xiangpu chairman; new committee composition Announcement 5 Oct 2026Governance reset
13 Oct 2026 (scheduled)Latest date for posting offer remittances JA 2 Oct 2026Process completion

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue rose from HKD 21 Mn in FY2021 to HKD 44.5 Mn in FY2025.
Max Sight Group Holdings Limited — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2021FY2022FY2023FY2024FY2025
Revenue2131.380.266.244.5
Cost of services—26.253.34632.4
Gross profit—5.126.920.312.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.